Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValbiotisXPAR:ALVAL -1.04%48 Equity-to-Asset is 0.48 as of Dec. 2025, which is 8% below its 10-year median of 0.52. GuruFocus rates XPAR:ALVAL with a GF Score™ of 48/100 and a GF Value™ of €1.45 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,994 Consumer Packaged Goods companies, Valbiotis ranks worse than 59.23% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Valbiotis's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €6.96 Mil. Valbiotis's Total Assets for the quarter that ended in Dec. 2025 was €14.39 Mil.
Therefore, Valbiotis's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.48.
The historical rank and industry rank for Valbiotis's Equity-to-Asset or its related term are showing as below:
XPAR:ALVAL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23 Med: 0.52 Max: 0.8
Current: 0.48
During the past 11 years, the highest Equity to Asset Ratio of Valbiotis was 0.80. The lowest was 0.23. And the median was 0.52.
XPAR:ALVAL's Equity-to-Asset is ranked worse than 59.23% of 1994
companies
in the Consumer Packaged Goods industry
Industry Median: 0.55
vs XPAR:ALVAL: 0.48
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Valbiotis Equity-to-Asset Related Terms
Valbiotis Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Valbiotis's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVAL vs KHC, GIS: Equity-to-Asset Comparison
For the Packaged Foods subindustry, Valbiotis's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Valbiotis's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Valbiotis's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valbiotis (XPAR:ALVAL) has a Equity-to-Asset of 0.48 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valbiotis and its competitors. This is near median its historical median of 0.52. Over the past decade, Valbiotis' Equity-to-Asset has ranged from 0.23 to 0.80. According to the industry distribution chart, Valbiotis ranks #1181 out of 1994 companies in the Consumer Packaged Goods industry, placing it in the top 59.2%.
Is Valbiotis' Equity-to-Asset too high?
Valbiotis' current Equity-to-Asset of 0.48 is near median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 0.80. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. Valbiotis' value of 0.48 is 12.7% below this industry median. Based on the distribution chart, Valbiotis ranks #1181 out of 1994 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Valbiotis has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Equity-to-Asset compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #1181 out of 1994 companies for Equity-to-Asset. This places Valbiotis in the lower half of its industry. The industry median Equity-to-Asset is 0.55. Valbiotis' value of 0.48 is 12.7% below this benchmark. Historically, Valbiotis' own Equity-to-Asset has ranged from 0.23 to 0.80 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.55, Valbiotis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,994 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valbiotis's current Equity-to-Asset of 0.48 is 12.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valbiotis and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current Equity-to-Asset is 0.48, which is near median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.45, compared to a current price of €0.86 — trading 40.7% below its estimated fair value. The current Equity-to-Asset is 0.48, which is near median its 10-year median of 0.52 and 12.7% below the Consumer Packaged Goods industry median of 0.55. Valbiotis' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Equity-to-Asset is 0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.86 is trading 40.7% below its estimated GF Value™ of €1.45.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
Equity-to-Asset: 0.48 (near median its 10-year median of 0.52)
GF Value™: €1.45 vs. price of €0.86 (40.7% below fair value)
Industry Position: 12.7% below the Consumer Packaged Goods median (#1181 of 1994)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
48GF Score
Get the complete analysis for XPAR:ALVAL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
